Drug combination shows promise

Rapamycin used in combination with dasatinib could be an effective treatment for breast cancer, according to a study published in the journal Cancer Research.

Although neither drug has proved effective on its own, the trial shows rapamycin, an inhibitor of the protein mTOR (mammalian target of rapamycin) and dasatinib, which blocks Src-family kinases (SFKs), work well together to block cancer cell growth.

"We found if you put the two drugs together, you have much better ability to kill tumors than applying either drug alone," says